StockData
MBX Biosciences, Inc. logo

MBX Biosciences, Inc. (MBX) stock

MBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$53.10−0.02 (-0.04%)

Close on Nov 17, 2026Market cap $2.56BP/E –Yield –

MBX Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

MBX Biosciences's operating cash flow for the twelve months ending Sep 30, 2026 was -$96.01M. For fiscal 2025 it was -$79.95M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$79.95M–
FY2024Dec 31, 2024-$54.68M–
FY2023Dec 31, 2023-$31.98M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$34.88M–
Q2 FY2026Jun 30, 2026-$22.62M–
Q1 FY2026Mar 31, 2026-$20.21M–
Q4 FY2025Dec 31, 2025-$18.30M–
Q3 FY2025Sep 30, 2025-$21.54M–
Q2 FY2025Jun 30, 2025-$17.43M–
Q1 FY2025Mar 31, 2025-$22.68M–
Q4 FY2024Dec 31, 2024-$16.04M–
Q3 FY2024Sep 30, 2024-$14.66M–
Q2 FY2024Jun 30, 2024-$13.27M–
Q1 FY2024Mar 31, 2024-$10.71M–
Q4 FY2023Dec 31, 2023-$11.15M–

More MBX Biosciences figures

See a number that looks wrong?